Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies
Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate pharmacokinetics (PK) of oral BCX1777.
Recurrent or Refractory T/NK-cell Malignancies
DRUG: forodesine hydrochloride|DRUG: forodesine hydrochloride|DRUG: forodesine hydrochloride|DRUG: forodesine hydrochloride
To evaluate the safety profile and tolerability of oral BCX1777 in patients with recurrent or refractory T/ NK-cell malignancies., March 2010|To evaluate pharmacokinetics (PK) of oral BCX1777, March 2010
To evaluate pharmacodynamics (PD) of oral BCX1777, March 2010|To correlate the plasma level of BCX1777 with plasma 2'-deoxyguanosine (dGuo), March 2010|To evaluate the efficacy of oral BCX1777, March 2010|To analyze cell surface marker in peripheral blood mononuclear cell, March 2010
Primary objectives are to evaluate the safety profile and tolerability of oral BCX1777 in each cohort of patients with recurrent or refractory T/NK-cell malignancies and to evaluate pharmacokinetics (PK) of oral BCX1777.